glp 1 agonist shortage The GLP-1 boom created one of the strangest health stories of the decade. Drugs built for diabetes and obesity became pop-culture products, then supply shortages opened the door to falsified versions. WHO An Ongoing Crisis: Semaglutide Shortage
Description
Ozempic and Mounjaro: What Sets Them Apart Ozempic (semaglutide) and Mounjaro (tirzepatide) are the two front-runners fueling the GLP-1 Revolution

Increased glycolytic enzyme pools in the cytoplasm allow for elevated glycolytic flux and glycolytic capacity, leading to faster ATP production and enhanced glucose-stimulated insulin secretion

Alternating between semaglutide and tirzepatide is an approach some patients and providers explore, though insurance coverage for such protocols can be challenging to navigate

PMID: 21980072
